Retrovirus MSRV and gliotoxic factor: Potential biological markers in multiple sclerosis;Retrovirus MSRV et proteine gliotoxique: Marqueurs biologiques potentiels dans la sclerose en plaques?

Annales de Biologie Clinique

Volumn 56, Issue 4, 1998, Pages 427-438

  Perron, H ^a  

^a BIOMÉRIEUX   (France)

Author keywords

Autoimmunity; Gliotoxin; Multiple sclerosis; Retrovirus; Superantigen

Indexed keywords

CYTOTOXIC FACTOR; GLIOTOXIN; SUPERANTIGEN; BIOLOGICAL MARKER;

AUTOIMMUNITY; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; DEMYELINATING NEUROPATHY; DIABETES MELLITUS; GLIA CELL; HUMAN; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PLASMA; RETROVIRUS; REVIEW; SJOEGREN SYNDROME; VIRUS PARTICLE; ANIMAL; BIOLOGICAL MODEL; ISOLATION AND PURIFICATION; PATHOLOGY; VIROLOGY;

ANIMALS; BIOLOGICAL MARKERS; GLIOTOXIN; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; RETROVIRIDAE;

EID: 0032111517     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Charcot JM. Histologie de la sclérose en plaques. Gaz Hop (Paris) 1868; 41: 554-66.
2. Beer S, Rosier KM, Hess CW. Diagnostic value of paraclinical tests in multiple sclerosis : relative sensitivities and specificities for reclassification according to the Poser committee criteria. J Neurol Neurosurg Psychiatry 1995; 59: 152-9.
3. Marie P. Sclérose en plaques et maladies infectieuses. Le progrès médical 1884; 12: 287-9.
4. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6; 382-427.
5. Talbot P. Implication des virus dans la sclérose en plaques. Médecine/Sciences 1995; 11: 837-43.
6. Matsiota P, Blancher A, Doyon B, et al. Comparative study of natural autoantibodies in the serum and cerebrospinal fluid of normal individuals and patients with multiple sclerosis and other neurological diseases. Ann Inst Pasteur/Immunol 1988; 139: 99-108.
7. Dal Canto MC, Melvold RW, Kim BS, Miller SD. Two models of multiple sclerosis : experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Microsc Res Tech 1995; 32: 215-29.
8. Field EJ. Immunological treatment for multiple sclerosis. Lancet 1989; 1: 1272.
9. Begovich AB, Helmuth RC, Oksenberg JR, et al. HLA-DP beta and susceptibility to multiple sclerosis : an analysis of caucasoid and Japanese patient populations. Hum Immunol 1990; 28: 365-72.
10. Bell JI, Lathrop GM. Multiple loci for multiple sclerosis. Nature Genet 1996; 13: 377-8.
11. James WH. Review of the contribution of twin studies in the search for non-genetic causes of multiple sclerosis. Neuroepidemiol 1996; 15: 132-41.
12. Gardner MB Genetic resistance to a retroviral neurologic disease in wild mice. In : Oldstone MBA, Koprowski H, eds. Retrovirus infections of the nervous system. Berlin, Springer-Verlag, Curr Top Microbiol Immunol 1990; 160: 3-10
13. Koprowski H, De Freitas EC, Harper ME, et al. Multiple sclerosis and Human T-cell lymphotropic retroviruses. Nature 1985; 318: 154-60.
14. Gessain A, Abel L, De The G, Vernant JC, Raverdy P, Guillard A. Lack of antibody to HTLV-I and HIV in patients with multiple sclerosis from France and French West Indies. Br Med J 1986; 293: 424-5.
15. Johnson RT. Nononcogenic retrovirus infections as models for chronic and relapsing human diseases : introduction. Rev Infect Dis 1985; 7: 66-7.
16. Rasmussen HB, Perron H, Clausen J. Do endogenous retroviruses and related genetic elements contribute to the development of inflammatory and degenerative nervous system diseases? Acta Neurol 1993; 88: 190-8.
17. Perron H, Geny C. Laurent A, et al. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989; 140: 551-61.
18. Haahr S, Sommerlund M, Moller-Larsen A, Nielsen R, Hansen HJ. Just another dubious virus in cells from a patient with multiple sclerosis? Lancet 1991; 337: 863-4.
19. Lan XY, Zeng Y, Zhang D, et al. Establishment of a human malignant lymphoma cell line carrying retrovirus-like particles with RT activity. Biomed Environ Sci 1994; 7: 1-12.
20. Perron H, Gratacap, Lalande B, et al. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991; 337: 862-3.
21. Perron H, Firouzi R, Tuke P, et al. and the collaborative research group on MS. Cell cultures and associated retrovirus in multiple sclerosis. Acta Neurol Scand 1997; 169s: 22-31.
22. LaMantia G, Maglione D, Pengue G, et al. Identification and characterization of novel human endogenous retroviral sequences preferentially expressed in undifferentiated embryonal carcinoma cells. Nucleic Acids Res 1991; 19: 1513-20.
23. Lefebvre S, Hubert B, Tekaia F, Brahic M, Bureau JF. Isolation from humain brain of six previously unreported cDNAs related to the reverse transcriptase of human endogenous retroviruses. AIDS Res Hum Retroviruses 1995; 11: 231-7.
24. Perron H, Carson JA, Bedin F, et al. and the collaborative research group on multiple sclerosis. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci USA 1997; 94: 7583-8.
25. Sonigo P, Barker C, Hunter E, Wain-Hobson S. Nucleotide sequence of Mason-Pfizer monkey virus : an immunosuppressive D-type retrovirus. Cell 1986; 45: 375-85.
26. Carson JA, Tuke PW, Giraud P, Paranhos-Baccala G, Perron H. Detection of virion-associated MSRV-RNA in serum of patients with multiple sclerosis. Lancet 1998; 351: 33.
27. Haahr S, Sommerlund M, Christensen T, Jensen AW, Hansen HJ, Moller-Larsen A. A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann NY Acad Sci 1994; 724: 148-56.
28. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985; 17: 371-7.
29. Ranger-Rogez S, Vidal E, Denis F. Le virus herpès humain de type 6 (HHV-6) est-il impliqué dans la survenue de maladies auto-immunes? Virologie 1997; 1: 301-12.
30. Perron H, Suh M, Lalande B, et al. Herpes Simplex Virus ICPO and ICP4 immediate-early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell-line from multiple sclerosis. J Gen Virol 1993; 74: 65-72.
31. Rasmussen HB, Christensen K, Clausen J. Three allelic forms of the human endogenous retrovirus, ERV3, and their frequencies in multiple sclerosis patients and healthy individuals. Autoimmunity 1996; 23: 111-7.
32. Liegler TJ, Blak PB. Direct detection of exogenous mouse mammary tumor virus sequences in lymphoid cells of BALB/cfC3H female mice. J Virol 1986; 59: 159-62.
33. Bai J, Zhu RY, Stedman K, et al. Unique long terminal repeat U3 sequences distinguish exogenous Jaagsiekte sheep retroviruses associated with ovine pulmonary carcinoma from endogenous loci in the sheep genome. J Virol 1996; 70: 3159-68.
34. Rudge P. Does a retrovirally encoded superantigen cause multiple sclerosis? J Neurol Neurosurg Psychiatry 1991; 54: 853-5.
35. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46.
36. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987; 139: 2593-7.
37. Rieger F, Amouri R, Benjelloun N, et al. Un facteur gliotoxique et la sclérose en plaques. CR Acad Sci (Paris) Life sciences 1996; 319: 343-50.
38. Ménard A, Amouri R, Dobransky T, et al. A gliotoxic factor in multiple sclerosis. J Neuro Sci 1998; 154: 209-21.
39. Poirier J, Fleury J, Ghérardi R. La barrière hémato-encéphalique. Données morphologiques. Rev Med Int 1983; 4: 131-44.
40. Gonzales-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH. Multiple sclerosis disease activity correlates with gadolinium enhancement magnetic resonance imaging. Ann Neurol 1987; 21: 300-6.
41. o 56 : Viral disease. Amsterdam, Elsevier, 1989.
42. Calder V, Owen S, Watson C, Feldmann M, Davidson A. MS : a localized immune disease of central nervous system. Immunol Today 1989; 10: 99-103.
43. Prineas JW. Pathology of early lesion in multiple sclerosis. Human Pathol 1975; 6: 23-7.
44. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38: 409-21.
45. Escourolle R, Hauw JJ, Lyon-Caen O. Principales données morphologiques, approches physiopathologiques et étiologiques de la sclérose en plaques. Rev Prat (Paris) 1980; 30: 2047-53.
46. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990; 250: 1593-6.
47. Ménard A, Amouri R, Michel M, et al. Gliotoxicity, reverse transcriplase activity and retroviral RNA in monocyte/macrophage culture supernatants from patients with multiple sclerosis. FEBS Lett 1997; 413: 477-85.
48. Ménard A, Pierig R, Pelletier J, et al. Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients. Neuroscience Letters 1998; 245: 49-52.
49. Malcus-Vocanson C, Giraud P, Broussolle E, Perron H, Mandrand B, Chazot G. A urinary marker for multiple sclerosis. Lancet 1998; 351: 1330.
50. Griffiths DJ, Venables PJ, Weiss RA, Boyd MT. A novel exogenous retrovirus sequence identified in humans. Virology 1997; 71: 2866-72.
51. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 1997; 25: 303-13.
52. Temin HM. Origin and general nature of retroviruses. In : Levy JA, eds. The retroviridae. New York : Plenum Press, 1992.